Related Experiment Video
Updated: Nov 11, 2025

Establishing Cell Lines Overexpressing DR3 to Assess the Apoptotic Response to Anti-mitotic Therapeutics
Published on: January 11, 2019
In vivo tumor growth inhibition by Solanum tuberosum aspartic protease 3 (StAP3) treatment
Irene L Ibañez1, Fernando F Muñoz2, Jorge Zoppi3
1Institute of Nanoscience and Nanotechnology (INN), National Atomic Energy Commission (CNEA), National Scientific and Technical Research Council (CONICET), Constituyentes Node, Av. General Paz 1499, (B1650KNA) San Martín, Buenos Aires, Argentina.
Abstract:
Solanum tuberosum aspartic Proteases (StAPs) show selective plasma membrane permeabilization, inducing cytotoxicity of cancer cells versus normal cells in vitro. Herein, we aimed to evaluate both StAP3 systemic toxicity and antitumoral activity against human melanoma in vivo. The toxicity of a single high dose of StAP3 (10 µg/g body weight, intraperitoneally) was assessed in a Balb/c mice model. Subcutaneous A375 human melanoma xenografts in athymic nude (nu/nu) mice were induced. Once tumors developed (mean larger dimension = 3.8 ± 0.09 mm), mice were StAP3-treated (6 µg/g body weight, subcutaneously under the tumor at a single dose). For both models, controls were treated with physiologic saline solution. StAP3-treated mice showed a significant inhibition of tumor growth (p < 0.05) compared with controls. No signs of toxicity were detected in StAP3-treated mice in both models. These results suggest the potential of these plant proteases as anticancer agents.

